Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3979159 | Bulletin du Cancer | 2011 | 5 Pages |
Abstract
Germ cell tumors are cured by cisplatin-based chemotherapy and secondary surgery. Patients with initial poor response to chemotherapy and relapsed disease patients have poor prognosis. Among different therapeutic approaches high dose chemotherapy with hematopoietic stem cell support has been studied. Despite the existence of a number of phase II trials and several well-conducted phase III trials, this approach is neither a standard nor an option in the setting of first line and first salvage treatment. A randomized phase III trial has recently been initiated and patients with relapsed disease should be offered to participate in the trial. Several selected indications could be discussed in further lines of treatment.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Christophe Massard, Aude Fléchon, Karim Fizazi, Jean-Pierre Droz,